EZH2 and lymphoma: Pharmacologic inhibitors of EZH2 are in clinical trials for diseases where PRC2/EZH2 hyperfunction is clearly linked to malignant transformation (such as lymphomas with activating EZH2 mutations or INI1-negative solid tumors).